Trials / Terminated
TerminatedNCT02365207
Intravesical BCG Administration to Patients With Invasive Bladder Cancer
Evaluating Local and Regional Immune Responses to Intravesical BCG Administration to Patients With Invasive Bladder Cancer
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- The University of Texas Health Science Center at San Antonio · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment response) BCG intravesically followed by a cystectomy.
Detailed description
Patients with muscle invasive (≥T1) bladder cancer will be given 3-6 treatments (based on treatment response) intravesical TICE® BCG. BCG is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. After completion of BCG treatments the patient will undergo a cystectomy. A portion of bladder tumor tissue and lymph nodes will be collected for research purposes during the cystectomy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BCG strain of Mycobacterium bovis | Invasive bladder cancer treated with 3-6 weeks of intravesical BCG |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2018-09-30
- Completion
- 2019-04-25
- First posted
- 2015-02-18
- Last updated
- 2019-11-05
- Results posted
- 2019-11-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02365207. Inclusion in this directory is not an endorsement.